Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

• Status: Completed
• Trial end date: 2019-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Increasing drug resistance presents a significant challenge to the efficacies of common empiric eradication regimens for Helicobacter pylori treatment in the mainland of China. Tailored therapy may be the best choice to achieve good efficacy, especially in patients with penicillin allergy. Few studies had evaluated the patients with penicillin allergy.This study is designed to evaluate the efficacy and safety of antibiotic sensitivity-based tailored therapy for Helicobacter pylori treatment in the patients with penicillin allergy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Bismuth; Citric Acid; Clarithromycin; Esomeprazole; Levofloxacin; Metronidazole; Ofloxacin; Penicillins; Potassium Citrate; Tetracycline

Criteria

Inclusion Criteria:

• Participants with penicillin allergy who have non-ulcer functional dyspepsia or scarred peptic ulcer disease

• Ability and willingness to participate in the study and to sign and give informed consent

• confirmed H. pylori infection

Exclusion Criteria:

• Patients without penicillin allergy

• Less than 18 years old

• With previous gastric surgery

• Major systemic diseases

• Pregnancy or lactation

• Allergy to any of the study drugs

• Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion